<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01665794</url>
  </required_header>
  <id_info>
    <org_study_id>12-1088</org_study_id>
    <secondary_id>NCI-2012-01168</secondary_id>
    <nct_id>NCT01665794</nct_id>
  </id_info>
  <brief_title>Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Multiple Myeloma Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the effects of adding carfilzomib to the combination of&#xD;
      pomalidomide and dexamethasone in sequential dose escalation cohorts in patients with&#xD;
      relapsed or refractory multiple myeloma. This portion of the study is complete.&#xD;
&#xD;
      This study will also investigate the effects of adding daratumumab to the combination of&#xD;
      carfilzomib, pomalidomide and dexamethasone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients receive carfilzomib, pomalidomide, and dexamethasone in 28 days treatment cycles.&#xD;
      Study treatment continues for as long a their myeloma does not worsen and they do not have&#xD;
      unacceptable side effects. After completion of study treatment, patients are followed for up&#xD;
      to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2012</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of carfilzomib when administered in combination with pomalidomide and dexamethasone</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Partial response rate after 4 courses according to International Myeloma Working Group (IMWG) criteria</measure>
    <time_frame>4 months</time_frame>
    <description>The proportion and exact 95% binomial confidence interval for the response rate will be reported adjusted for the two-stage design of this trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rates of carfilzomib, pomalidomide, dexamethasone, and daratumumab dosing according to International Myeloma Working Group (IMWG) criteria</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as at least a partial response to therapy, will be reported along with its exact 95% binomial confidence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Estimated using the product-limit method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>From the date of the clinical examination which confirmed the response, until the date of disease progression, or censoring at the date of last clinical follow-up up to 2 years</time_frame>
    <description>Assessed conditional upon achieving at least a partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From the date of first therapy until the date of documented disease progression or death up to 2 years</time_frame>
    <description>Estimated using the product-limit method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Estimated using the product-limit method of Kaplan and Meier.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">101</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>PdC Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive carfilzomib, pomalidomide, and dexamethasone at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PdC + Dara Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive carfilzomib, pomalidomide, dexamethasone, and daratumumab at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Pomalidomide taken orally at assigned dose.</description>
    <arm_group_label>PdC + Dara Group</arm_group_label>
    <arm_group_label>PdC Group</arm_group_label>
    <other_name>CC-4047</other_name>
    <other_name>Pomalyst(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Carfilzomib given by intravenous (IV) infusion at assigned dose.</description>
    <arm_group_label>PdC + Dara Group</arm_group_label>
    <arm_group_label>PdC Group</arm_group_label>
    <other_name>Kyprolis (R)</other_name>
    <other_name>PR-171</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Dexamethasone taken orally of given by IV infusion.</description>
    <arm_group_label>PdC + Dara Group</arm_group_label>
    <arm_group_label>PdC Group</arm_group_label>
    <other_name>Aeroseb-Dex</other_name>
    <other_name>Decaderm</other_name>
    <other_name>Decadron</other_name>
    <other_name>DM</other_name>
    <other_name>DXM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Daratumumab given by intravenous (IV) infusion at assigned dose.</description>
    <arm_group_label>PdC + Dara Group</arm_group_label>
    <other_name>Daralex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Relapsed and relapsed/refractory multiple myeloma requiring systemic therapy&#xD;
&#xD;
          -  Failed at least one prior treatment for multiple myeloma (must have received&#xD;
             lenalidomide)&#xD;
&#xD;
               -  To be enrolled as second line therapy: Must be refractory to lenalidomide&#xD;
                  (progression on therapy or within 60 days of lenalidomide dosing)&#xD;
&#xD;
          -  Measurable disease, as indicated by one or more of the following:&#xD;
&#xD;
               -  Serum M-protein &gt;= 0.5 g/dL&#xD;
&#xD;
               -  Urine M-protein &gt;= 200 mg/24 hours&#xD;
&#xD;
               -  If serum protein electrophoresis is felt to be unreliable for routine M-protein&#xD;
                  measurement, then quantitative immunoglobulin levels are acceptable&#xD;
&#xD;
               -  Involved serum free light chains â‰¥ 10 mg/dL (free light change ratio must be&#xD;
                  abnormal)&#xD;
&#xD;
          -  Aged 18 years or older&#xD;
&#xD;
          -  Life expectancy of more than 3 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Adequate Liver Function&#xD;
&#xD;
               -  Bilirubin &lt; 1.5 times the upper limit of normal (ULN)&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) &lt; 2.5 times ULN&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) &lt; 2.5 times ULN&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1.0 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin &gt;= 8 g/dL&#xD;
&#xD;
          -  Platelet count &gt;= 75 x 10^9/L (should be independent of platelet transfusions for at&#xD;
             least 2 weeks)&#xD;
&#xD;
          -  Calculated or measured creatinine clearance of &gt;= 30 mL/minute&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Negative pregnancy test (for women of childbearing potential) within 10-14 days of&#xD;
             starting study treatment and again within 24 hours of first pomalidomide dose&#xD;
&#xD;
          -  Must agree to practice abstinence or use two acceptable methods of birth control&#xD;
&#xD;
          -  Men must agree to use latex condom during sexual contact with women of childbearing&#xD;
             potential (even if post vasectomy)&#xD;
&#xD;
          -  Must agree to adhere to all study requirements, visit schedule, outpatient treatment,&#xD;
             required concomitant medications, and laboratory monitoring&#xD;
&#xD;
          -  Must register to mandatory POMALYST REMSâ„¢ program and be willing and able to comply&#xD;
             with the requirements of the POMALYST REMSâ„¢ program&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients for whom there is the prospect of stem cell transplantation in the next 6&#xD;
             months in the treatment plan are excluded&#xD;
&#xD;
          -  POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and&#xD;
             skin changes)&#xD;
&#xD;
          -  Plasma cell leukemia&#xD;
&#xD;
          -  WaldenstrÃ¶m's macroglobulinemia or immunoglobulin M (IgM) myeloma&#xD;
&#xD;
          -  Radiotherapy to multiple sites or immunotherapy within 4 weeks before start of&#xD;
             protocol treatment (localized radiotherapy to a single site at least 1 week before&#xD;
             start is permissible)&#xD;
&#xD;
          -  Participation in an investigational therapeutic study within 3 weeks or within 5 drug&#xD;
             half lives (t1/2) prior to first dose, whichever time is greater&#xD;
&#xD;
          -  Patients known to be refractory to any proteasome inhibitor other than bortezomib or&#xD;
             carfilzomib&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  History of allergy to mannitol or prior hypersensitivity to thalidomide, lenalidomide&#xD;
             or pomalidomide&#xD;
&#xD;
          -  Major surgery within 3 weeks prior to first dose,&#xD;
&#xD;
          -  Prior peripheral stem cell transplant within 12 weeks of study enrollment&#xD;
&#xD;
          -  Has received any anti-cancer therapy including chemotherapy, immunotherapy,&#xD;
             radiotherapy, hormonal (with the exception of hormones for thyroid conditions or&#xD;
             estrogen replacement therapy [ERT]), or any investigational therapy within 21 days of&#xD;
             enrollment&#xD;
&#xD;
          -  Myocardial infarction within 6 months prior to enrollment, New York Heart Associate&#xD;
             (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled&#xD;
             ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active&#xD;
             conduction system abnormalities&#xD;
&#xD;
          -  Uncontrolled hypertension or diabetes&#xD;
&#xD;
          -  Acute active infection requiring systemic antibiotics, antivirals, or anti fungals&#xD;
             within two weeks prior to first dose&#xD;
&#xD;
          -  Known or suspected human immunodeficiency (HIV) infection, known HIV seropositivity&#xD;
&#xD;
          -  Active hepatitis A, B, or C infection&#xD;
&#xD;
          -  Non-hematologic malignancy within the past 3 years except adequately treated basal&#xD;
             cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix or&#xD;
             breast, prostate cancer &lt; Gleason grade 6 with stable prostate specific antigen levels&#xD;
             or cancer considered cured by surgical resection alone&#xD;
&#xD;
          -  Any clinically significant medical disease or condition that, in the investigator's&#xD;
             opinion, may interfere with protocol adherence or a subject's ability to give informed&#xD;
             consent&#xD;
&#xD;
          -  Significant neuropathy (grades 3-4, or grade 2 with pain) at the time of the first&#xD;
             dose and/or within 14 days before enrollment&#xD;
&#xD;
          -  Contraindications to any of the required concomitant drugs, including proton-pump&#xD;
             inhibitor (eg, lansoprazole), enteric-coated aspirin, allopurinol or if a history of&#xD;
             prior thrombotic disease, warfarin or low molecular weight heparin&#xD;
&#xD;
          -  Subjects in whom the required program of PO and IV fluid hydration is contraindicated,&#xD;
             eg, due to pre-existing pulmonary, cardiac, or renal impairment&#xD;
&#xD;
          -  Subjects with known or suspected amyloidosis of any organ&#xD;
&#xD;
          -  Subjects with pleural effusions requiring thoracentesis or ascites requiring&#xD;
             paracentesis&#xD;
&#xD;
          -  Prior exposure to daratumumab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrzej Jakubowiak</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrzej J. Jakubowiak</last_name>
      <phone>773-834-1592</phone>
      <email>ajakubowiak@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Andrzej J. Jakubowiak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wayne State University - Karmonos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Berdeja, MD</last_name>
      <phone>615-329-7274</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Health Network - Princess Margaret Cancer Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>MISG 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 13, 2012</study_first_submitted>
  <study_first_submitted_qc>August 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2012</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

